127 related articles for article (PubMed ID: 19275717)
1. Caulerpenyne binding to tubulin: structural modifications by a non conventional pharmacological agent.
Bourdron J; Barbier P; Allegro D; Villard C; Lafitte D; Commeiras L; Parrain JL; Peyrot V
Med Chem; 2009 Mar; 5(2):182-90. PubMed ID: 19275717
[TBL] [Abstract][Full Text] [Related]
2. Interaction of the antitumor compound cryptophycin-52 with tubulin.
Panda D; Ananthnarayan V; Larson G; Shih C; Jordan MA; Wilson L
Biochemistry; 2000 Nov; 39(46):14121-7. PubMed ID: 11087360
[TBL] [Abstract][Full Text] [Related]
3. Interaction of a fluorescent derivative of paclitaxel (Taxol) with microtubules and tubulin-colchicine.
Han Y; Chaudhary AG; Chordia MD; Sackett DL; Perez-Ramirez B; Kingston DG; Bane S
Biochemistry; 1996 Nov; 35(45):14173-83. PubMed ID: 8916903
[TBL] [Abstract][Full Text] [Related]
4. The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach.
Chaudhuri AR; Seetharamalu P; Schwarz PM; Hausheer FH; Ludueña RF
J Mol Biol; 2000 Nov; 303(5):679-92. PubMed ID: 11061968
[TBL] [Abstract][Full Text] [Related]
5. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine.
Pineda O; Farràs J; Maccari L; Manetti F; Botta M; Vilarrasa J
Bioorg Med Chem Lett; 2004 Oct; 14(19):4825-9. PubMed ID: 15341932
[TBL] [Abstract][Full Text] [Related]
6. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.
Matthew S; Chen QY; Ratnayake R; Fermaintt CS; Lucena-Agell D; Bonato F; Prota AE; Lim ST; Wang X; Díaz JF; Risinger AL; Paul VJ; Oliva MÁ; Luesch H
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619102
[TBL] [Abstract][Full Text] [Related]
7. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
Mooberry SL; Taoka CR; Busquets L
Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
[TBL] [Abstract][Full Text] [Related]
8. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
Jordan A; Hadfield JA; Lawrence NJ; McGown AT
Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
[TBL] [Abstract][Full Text] [Related]
9. Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
Naaz F; Haider MR; Shafi S; Yar MS
Eur J Med Chem; 2019 Jun; 171():310-331. PubMed ID: 30953881
[TBL] [Abstract][Full Text] [Related]
10. Effect-directed analysis reveals inhibition of zebrafish uptake transporter Oatp1d1 by caulerpenyne, a major secondary metabolite from the invasive marine alga Caulerpa taxifolia.
Marić P; Ahel M; Senta I; Terzić S; Mikac I; Žuljević A; Smital T
Chemosphere; 2017 May; 174():643-654. PubMed ID: 28199941
[TBL] [Abstract][Full Text] [Related]
11. Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites.
Buey RM; Calvo E; Barasoain I; Pineda O; Edler MC; Matesanz R; Cerezo G; Vanderwal CD; Day BW; Sorensen EJ; López JA; Andreu JM; Hamel E; Díaz JF
Nat Chem Biol; 2007 Feb; 3(2):117-25. PubMed ID: 17206139
[TBL] [Abstract][Full Text] [Related]
12. Interaction of cryptophycin 1 with tubulin and microtubules.
Kerksiek K; Mejillano MR; Schwartz RE; Georg GI; Himes RH
FEBS Lett; 1995 Dec; 377(1):59-61. PubMed ID: 8543019
[TBL] [Abstract][Full Text] [Related]
13. Physiochemical aspects of tubulin-interacting antimitotic drugs.
Correia JJ; Lobert S
Curr Pharm Des; 2001 Sep; 7(13):1213-28. PubMed ID: 11472263
[TBL] [Abstract][Full Text] [Related]
14. Sulfhydryl groups of Mimosa pudica tubulin implicated in colchicine binding and polymerization in vitro.
Roychaudhuri A; Biswas S
Arch Biochem Biophys; 1992 May; 294(2):353-60. PubMed ID: 1567190
[TBL] [Abstract][Full Text] [Related]
15. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.
Lindamulage IK; Vu HY; Karthikeyan C; Knockleby J; Lee YF; Trivedi P; Lee H
Sci Rep; 2017 Aug; 7(1):10298. PubMed ID: 28860494
[TBL] [Abstract][Full Text] [Related]
16. Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin.
Li CM; Lu Y; Ahn S; Narayanan R; Miller DD; Dalton JT
J Mass Spectrom; 2010 Oct; 45(10):1160-6. PubMed ID: 20814887
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
Li L; Jiang S; Li X; Liu Y; Su J; Chen J
Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
[TBL] [Abstract][Full Text] [Related]
18. Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin.
Mitra A; Sept D
Biochemistry; 2004 Nov; 43(44):13955-62. PubMed ID: 15518544
[TBL] [Abstract][Full Text] [Related]
19. Electrostatic contributions to colchicine binding within tubulin isotypes.
Huzil JT; Barakat K; Tuszynski JA
Electromagn Biol Med; 2009; 28(4):355-64. PubMed ID: 20017626
[TBL] [Abstract][Full Text] [Related]
20. Fluorescence spectroscopic methods to analyze drug-tubulin interactions.
Bhattacharyya B; Kapoor S; Panda D
Methods Cell Biol; 2010; 95():301-29. PubMed ID: 20466142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
